10/28/2025
Yesterday at , LTLinx heard from Joseph Dieleman, PhD (UW / IHME), who broke down where healthcare dollars actually go, why some areas spend more than others, and how inefficiency shows up in the system. His work tracks U.S. and global health spending by condition, payer, and geography to understand whether we’re truly getting impact for what we spend. 
Then they opened it up to an incredible panel from industry, venture, and regulation — Sara Dutta (Novo Nordisk ), Jason Fontana (Wayfinder Biosciences ), Joe Horsman (Madrona Venture Group), and Eva Yin (Wilson Sonsini Goodrich & Rosati) — on how AI is being used right now in drug discovery and operational decision-making. The message was clear: AI is powerful, but it doesn’t replace the human judgment, ethics, and care required to deliver real outcomes in health and life sciences. 
Huge thanks to and Creative Destruction Lab UW for bringing together science, capital, and operators in the same room — and to moderator
Bulat Idrisov for asking the real questions: Where is the waste? Where is the opportunity? And where can AI make healthcare not just cheaper, but actually better? 
